A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis
- 31 May 2003
- journal article
- research article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 1 (3) , 170-173
- https://doi.org/10.1016/s1542-3565(03)70032-9
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control studyAmerican Journal of Gastroenterology, 2000
- Stress and Exacerbation in Ulcerative Colitis: A Prospective Study of Patients Enrolled in RemissionAmerican Journal of Gastroenterology, 2000
- Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 monthsAlimentary Pharmacology & Therapeutics, 1998
- Effects of smoking on the presentation and clinical course of inflammatory bowel diseaseEuropean Journal of Gastroenterology & Hepatology, 1997
- Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease.Gut, 1997
- An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative ColitisAnnals of Internal Medicine, 1996
- Coated Oral 5-Aminosalicylic Acid (Claversal) Is Equivalent to Sulfasalazine for Remission Maintenance in Ulcerative ColitisJournal of Clinical Gastroenterology, 1995
- Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitisEuropean Journal of Gastroenterology & Hepatology, 1995
- Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitisDigestive Diseases and Sciences, 1995
- Cigarette Smoking and Ulcerative Colitis: A Case-Control StudyMayo Clinic Proceedings, 1994